title: The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage.
abstract: The role of serum uric acid (SUA) in the context of adverse cardiovascular events in hypertensive subjects is controversial. Additionally, the relationship between SUA and indices of target organ damage is not well defined in this setting. Towards this end, we studied 842 consecutive nondiabetic patients with stage I-II essential hypertension (office blood pressure=148/95 mmHg, aged 53.4 years), referred to our outpatient hypertensive unit within a period of 4 years. According to the urinary albumin excretion (UAE), the study population was classified into those with microalbuminuria [MA(+), UAE=20-200 mg/24 h, n=222] and those without MA [MA (-), UAE< 20 mg/24 h, n=620]. Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (-), n=537]. SUA levels were higher by 0.4 mg/dl, (P=0.04) in group MA (+) compared with the group MA (-), while no difference was observed between groups LVH (+) and LVH (-) (P=NS). In the entire population, SUA was correlated with body mass index (BMI) (r=0.17, P<0.001), waist/hip ratio (r=0.3, P<0.001), office systolic blood pressure (SBP) (r=0.14, P<0.05), triglycerides levels (r=0.25, P<0.001), UAE (r=0.35, P<0.001) and HDL (r=-0.26, P<0.001). Multiple regression analysis demonstrated that SUA was significantly related with BMI, office SBP and UAE (P<0.05). In conclusion, increased SUA levels are associated with MA but not with LVH in essential hypertensive subjects. Whether these inter-relationships may elucidate the clinical positioning of augmented SUA in this setting remains to be clarified in future studies.
authors.affiliation: Department of Cardiology, Athens University, Hippokration Hospital, Athens, Greece. ktsioufis@hippocratio.gr
authors.forename: C
authors.initials: C
authors.lastname: Tsioufis
authors.forename: D
authors.initials: D
authors.lastname: Chatzis
authors.forename: E
authors.initials: E
authors.lastname: Vezali
authors.forename: K
authors.initials: K
authors.lastname: Dimitriadis
authors.forename: D
authors.initials: D
authors.lastname: Antoniadis
authors.forename: A
authors.initials: A
authors.lastname: Zervoudaki
authors.forename: S
authors.initials: S
authors.lastname: Lalos
authors.forename: I
authors.initials: I
authors.lastname: Kallikazaros
authors.forename: C
authors.initials: C
authors.lastname: Stefanadis
authors.forename: P
authors.initials: P
authors.lastname: Toutouzas
mesh_terms: D000419:Albuminuria / Q000175:diagnosis / Q000209:etiology* / Q000652:urine; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D010045:Outpatients; D012044:Regression Analysis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014527:Uric Acid / Q000097:blood*
chemical_list: D015415:Biomarkers; D014527:Uric Acid